Berkeley Lights, Inc.

Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PhenomeX is enabling researchers to take advantage of each cell's full potential and launch the next phase of functional cell biology that will improve human health. We give researchers the most thorough understanding of how cells function and a detailed picture of each cell's behaviour.

EMERYVILLE, Calif. and MARSEILLE, France, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and MImAbs SAS, an emerging CRO that discovers and develops antibodies for immunotechnology therapeutics and research, today announced the acquisition of the Berkeley Lights Beacon® system via a TechAccess subscription to help further its mission of helping its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.

Berkeley Lights Debuts in France as MImAbs Acquires the Beacon® Optofluidic System for Antibody Discovery

EMERYVILLE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference.

Berkeley Lights to Participate in the Stifel 2021 Virtual Healthcare Conference

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Berkeley Lights To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 5, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Berkeley Lights Inc. ("Berkeley Lights" or the "Company") (NASDAQ: BLI).If you suffered losses exceeding $100,000 investing in Berkeley Lights stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for...

Berkeley Lights Shareholder Alert

Berkeley Lights, Inc. (BLI) CEO Eric Hobbs on Q3 2021 Results - Earnings Call Transcript

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -30.43% and 3.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Berkeley Lights, Inc. (BLI) Reports Q3 Loss, Tops Revenue Estimates

Record third quarter 2021 revenue grew 34% year over year Record third quarter 2021 revenue grew 34% year over year

Berkeley Lights Reports Third Quarter 2021 Financial Results

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Berkeley Lights To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 1, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Berkeley Lights Inc. ("Berkeley Lights" or the "Company") (NASDAQ: BLI).If you suffered losses exceeding $100,000 investing in Berkeley Lights stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...

Berkeley Lights Investor Alert

Abveris, top clinical research organization, to report two-year data and results achieved from the Berkeley Lights Beacon® Optofluidic System for antibody discovery Abveris, top clinical research organization, to report two-year data and results achieved from the Berkeley Lights Beacon® Optofluidic System for antibody discovery

Berkeley Lights to Present on Cell Line Development of Complex Molecules and Accelerating Antibody Discovery Against Difficult Targets at 13th Annual PEGS Europe

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Berkeley Lights To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Berkeley Lights Inc. ("Berkeley Lights" or the "Company") (NASDAQ: BLI).If you suffered losses exceeding $100,000 investing in Berkeley Lights stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here...

Berkeley Lights Update

Berkeley Lights, Inc. (BLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Berkeley Lights, Inc. (BLI) to Report a Decline in Earnings: What to Look Out for

GSK adds antibody discovery workflow to current cell line development process GSK adds antibody discovery workflow to current cell line development process

Berkeley Lights Announces GSK Acquires Third Beacon® Optofluidic System to Expand Antibody Therapeutics Development

Berkeley Lights, Inc. (BLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Berkeley Lights, Inc. (BLI): Can Its 6.2% Jump Turn into More Strength?

The stock price of Berkeley Lights Inc (NASDAQ: BLI) increased by over 13% today. This is why it happened.

BLI Stock: Why It Increased Today

Record quarterly revenue and instrument placements

Berkeley Lights Reports Preliminary Third Quarter 2021 Results

San Francisco, California--(Newsfile Corp. - October 8, 2021) - Hagens Berman urges Berkeley Lights, Inc. (NASDAQ: BLI) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/BLI Contact An Attorney Now: BLI@hbsslaw.com 844-916-0895Berkeley Lights, Inc. (BLI) Investigation: The investigation focuses on the accuracy of cell biology specialist Berkeley Lights' statements concerning its only product, the Beacon: a $2 million lab instrument that the Company touts...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Berkeley Lights (BLI) Investors with Significant Loss to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development

Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development

San Francisco, California--(Newsfile Corp. - October 1, 2021) - Hagens Berman urges Berkeley Lights, Inc. (NASDAQ: BLI) investors with significant losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/BLIContact An Attorney Now: BLI@hbsslaw.com844-916-0895Berkeley Lights, Inc. (BLI) Investigation: The investigation focuses on the accuracy of cell biology specialist Berkeley Lights' statements concerning its only product, the Beacon: a $2 million lab instrument that the Company touts is "a better, more advanced way to process and...

BLI INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Berkeley Lights (BLI) Investors with Significant Loss to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

On September 5th, Berkeley Lights was hit by short seller Scorpion Capital, knocking the stock down roughly 30%.

Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions

Shares of Berkeley Lights Inc. bounced sharply Friday, after the cell biology company responded to a short seller's report that had helped fuel a brutal selloff to record lows, and as analysts also came to the company's defense.

Berkeley Lights calls short seller's report ‘highly misleading,' and stock bounces sharply off record low

San Francisco, California--(Newsfile Corp. - September 17, 2021) - Hagens Berman urges Berkeley Lights, Inc. (NASDAQ: BLI) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/BLI Contact An Attorney Now: BLI@hbsslaw.com 844-916-0895Berkeley Lights, Inc. (BLI) Investigation: The investigation focuses on the accuracy of cell biology specialist Berkeley Lights' statements concerning its only product, the Beacon: a $2 million lab instrument that the Company touts...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Announces Investigation into Berkeley Lights (BLI) and Possible Securities Law Violations, Encourages Investors with Significant Loss to Contact Firm's Attorneys Now

NEW YORK--(BUSINESS WIRE)---- $BLI--The law firm of Kirby McInerney LLP is investigating potential claims against Berkeley Lights, Inc. (“Berkeley Lights” or the “Company”) (NASDAQ: BLI). The investigation concerns whether Berkeley Lights has violated the federal securities laws and/or engaged in other unlawful business practices. On September 15, 2021, Scorpion Capital published a research report, alleging, among other things, that Berkeley Lights' customers “allege they were ‘tricked,' misled, or over

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Berkeley Lights, Inc. (BLI) Investors

A short seller's stinging Twitter diatribe against the company continues to affect investor sentiment.

Why Berkeley Lights Fell Again Today, Despite Bullish New Analyst Notes

Boston, Massachusetts--(Newsfile Corp. - September 16, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations against Berkeley Lights, Inc. (NASDAQ: BLI) ("Berkeley Lights" or the "Company"), a "digital cell biology company" with headquarters in Emeryville, California.In July 2020, Berkeley Lights closed its initial public offering ("IPO"), in which the Company sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise...

BLI Alert: Berman Tabacco Announces Investigation of Berkeley Lights, Inc. for Potential Securities Law Violations

BENSALEM, Pa.--(BUSINESS WIRE)---- $BLI #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Berkeley Lights Inc. (“Berkeley Lights” or the “Company”) (NASDAQ: BLI) investors concerning the Company's possible violations of federal securities laws. On September 15, 2021, Scorpion Capital published a research report, alleging, among other things, that Berkeley Lights' customers “allege they were ‘tricked,' misled, or over-promised into buying a $2 million lemon” and that the Company's “

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Berkeley Lights Inc. (BLI) on Behalf of Investors

New York, New York--(Newsfile Corp. - September 15, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Berkeley Lights, Inc. (NASDAQ: BLI) common stock.Berkeley Lights is a digital cell biology company that focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights sells several machines that are used in a medical setting to perform various functions on cells. In...

News for Berkeley Lights, Inc. Stock (BLI)